retatrutide phase 3 trial dosage just posted the biggest weight-loss numbers ever recorded for a drug — 28.3% (≈70 lb) average in 3, with 45% of people hitting 30%+ loss, territory once reserved for bariatric retatrutide safety profile produces up

Luis AS, Hansson GC

Several studies, such as this one, have reported significant pain with water-based injections, and little to no pain with those prepared in saline

In phase 2, NTLA-2002 25 mg (n = 10) and 50 mg (n = 11) reduced attacks by 75%-77% vs placebo (n = 3

The absence of additive benefit across most clinical outcomes in the comparison between GLP-1RA plus SGLT2i and GLP-1RA monotherapy suggests that the observed effect may be predominantly driven by GLP-1RA alone, rather than a synergistic effect of the combination

Compared with patients using other second-line antidiabetic drugs, GLP-1 RA use was associated with a 15% increased risk of NAION